Marinus Pharmaceuticals, Inc. (MRNS): Price and Financial Metrics


Marinus Pharmaceuticals, Inc. (MRNS): $4.23

0.21 (+5.22%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MRNS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

MRNS POWR Grades

  • Sentiment is the dimension where MRNS ranks best; there it ranks ahead of 93.15% of US stocks.
  • The strongest trend for MRNS is in Momentum, which has been heading up over the past 26 weeks.
  • MRNS's current lowest rank is in the Stability metric (where it is better than 24.68% of US stocks).

MRNS Stock Summary

  • MRNS's price/sales ratio is 7.84; that's higher than the P/S ratio of 85.67% of US stocks.
  • With a year-over-year growth in debt of 74.42%, MARINUS PHARMACEUTICALS INC's debt growth rate surpasses 85.05% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, MARINUS PHARMACEUTICALS INC is reporting a growth rate of -95.95%; that's higher than just 15.26% of US stocks.
  • Stocks that are quantitatively similar to MRNS, based on their financial statements, market capitalization, and price volatility, are PXLW, SPCE, LXRX, CDXS, and FBIO.
  • Visit MRNS's SEC page to see the company's official filings. To visit the company's web site, go to www.marinuspharma.com.

MRNS Valuation Summary

  • In comparison to the median Healthcare stock, MRNS's price/sales ratio is 81.25% higher, now standing at 8.7.
  • Over the past 102 months, MRNS's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for MRNS.

Stock Date P/S P/B P/E EV/EBIT
MRNS 2022-12-05 8.7 2.1 -11.1 -21.2
MRNS 2022-12-02 8.8 2.1 -11.3 -21.9
MRNS 2022-12-01 8.9 2.2 -11.5 -22.6
MRNS 2022-11-30 9.0 2.2 -11.5 -22.9
MRNS 2022-11-29 9.0 2.2 -11.5 -23.0
MRNS 2022-11-28 8.7 2.1 -11.2 -21.4

MRNS Growth Metrics

    Its 2 year net cashflow from operations growth rate is now at -31.27%.
  • Its 4 year net income to common stockholders growth rate is now at -141.56%.
  • Its year over year cash and equivalents growth rate is now at 2.31%.
MRNS's revenue has moved up $14,407,000 over the prior 15 months.

The table below shows MRNS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 19.836 -112.722 -15.465
2022-06-30 27.61 -77.674 -106.606
2022-03-31 27.725 -66.957 -90.996
2021-12-31 15.345 -55.477 -98.776
2021-09-30 15.372 -50.125 -87.94
2021-06-30 5.429 -69.997 -84.092

MRNS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MRNS has a Quality Grade of D, ranking ahead of 11.62% of graded US stocks.
  • MRNS's asset turnover comes in at 0 -- ranking 440th of 682 Pharmaceutical Products stocks.
  • PPBT, TEVA, and PTE are the stocks whose asset turnover ratios are most correlated with MRNS.

The table below shows MRNS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0 NA -66.832
2021-03-31 0 NA -93.470
2020-12-31 0 NA -20.937
2020-09-30 0 NA -22.684
2020-06-30 0 NA -28.712
2020-03-31 0 NA -57.851

MRNS Price Target

For more insight on analysts targets of MRNS, see our MRNS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $29.88 Average Broker Recommendation 1.25 (Strong Buy)

MRNS Stock Price Chart Interactive Chart >

Price chart for MRNS

MRNS Price/Volume Stats

Current price $4.23 52-week high $13.15
Prev. close $4.02 52-week low $3.95
Day low $3.98 Volume 229,800
Day high $4.34 Avg. volume 308,411
50-day MA $5.29 Dividend yield N/A
200-day MA $6.22 Market Cap 157.34M

Marinus Pharmaceuticals, Inc. (MRNS) Company Bio


Marinus Pharmaceuticals is a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics. The company was founded in 2003 and is based in Radnor, Pennsylvania.


MRNS Latest News Stream


Event/Time News Detail
Loading, please wait...

MRNS Latest Social Stream


Loading social stream, please wait...

View Full MRNS Social Stream

Latest MRNS News From Around the Web

Below are the latest news stories about MARINUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate MRNS as an investment opportunity.

Marinus Pharmaceuticals Announces Presentations and Investor Event at American Epilepsy Society 2022 Annual Meeting

RADNOR, Pa., November 30, 2022--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that ganaxolone data from three abstracts, including one late-breaking abstract, will be presented at the upcoming 2022 American Epilepsy Society (AES) Annual Meeting, which will be held December 2-6, 2022, in Nashville, TN. Marinus will also host a scientific exhibit and investor breakfast event

Yahoo | November 30, 2022

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

RADNOR, Pa., November 18, 2022--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to 3 new employees. The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 71,700 shares of its common stock (the "Common Stock") as inducements material to the employees entering

Yahoo | November 18, 2022

Marinus Pharmaceuticals signs collaboration deal worth up to $266M with Chinese biotech firm

A Main Line pharmaceutical company could earn more than $266 million under a collaboration and supply agreement it signed with a Chinese biotech firm on Thursday. Under the terms of the deal, Marinus Pharmaceuticals (NASDAQ: MRNS) of Radnor will receive a $10 million upfront payment from Shanghai-based Tenacia Biotechnology Co. in return for the exclusive rights to develop and commercialize oral and intravenous formulations of ganaxolone in Mainland China, Hong Kong, Macau and Taiwan. Marinus is also eligible to receive up to an additional $256 million in cash milestone payments that are contingent on hitting a series of regulatory, clinical and commercial milestones, along with tiered low double-digit royalty payments based on sales of any approved products in China.

Yahoo | November 17, 2022

Marinus Pharma, Tenacia Biotech Ink Ganaxolone Agreement In China

Marinus Pharmaceuticals Inc (NASDAQ: MRNS) has entered into a collaboration and supply agreement with Tenacia Biotechnology (Shanghai) Co., Ltd., a China-based biotechnology company focused on the development of treatments for central nervous system (CNS) disorders. Under the terms of the agreement, Tenacia will receive exclusive rights to develop and commercialize certain formulations of ganaxolone in Mainland China, Hong Kong, Macau, and Taiwan, including the current oral and intravenous (IV)

Yahoo | November 17, 2022

Marinus Pharmaceuticals Announces Collaboration with Tenacia Biotechnology for Ganaxolone Development and Commercialization in China

RADNOR, Pa., November 17, 2022--Marinus Pharmaceuticals Announces Collaboration with Tenacia Biotechnology for Ganaxolone Development and Commercialization in China

Yahoo | November 17, 2022

Read More 'MRNS' Stories Here

MRNS Price Returns

1-mo -9.03%
3-mo -36.68%
6-mo -4.30%
1-year -61.82%
3-year -16.73%
5-year -86.55%
YTD -64.39%
2021 -2.62%
2020 41.20%
2019 -24.74%
2018 -64.83%
2017 707.92%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.2399 seconds.